Zhejiang Starry Pharmaceutical Co Ltd
SSE:603520

Watchlist Manager
Zhejiang Starry Pharmaceutical Co Ltd Logo
Zhejiang Starry Pharmaceutical Co Ltd
SSE:603520
Watchlist
Price: 9.73 CNY -0.71% Market Closed
Market Cap: 4.3B CNY

Zhejiang Starry Pharmaceutical Co Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Zhejiang Starry Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Starry Pharmaceutical Co Ltd
SSE:603520
Cash from Operating Activities
ÂĄ336.3m
CAGR 3-Years
33%
CAGR 5-Years
12%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Operating Activities
ÂĄ3.9B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Operating Activities
ÂĄ501.5m
CAGR 3-Years
-56%
CAGR 5-Years
N/A
CAGR 10-Years
4%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Operating Activities
ÂĄ11.9B
CAGR 3-Years
60%
CAGR 5-Years
18%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Operating Activities
ÂĄ4.7B
CAGR 3-Years
95%
CAGR 5-Years
-3%
CAGR 10-Years
8%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Operating Activities
ÂĄ4.1B
CAGR 3-Years
N/A
CAGR 5-Years
171%
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Starry Pharmaceutical Co Ltd
Glance View

Market Cap
4.3B CNY
Industry
Pharmaceuticals

Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of active ingredient and intermediate X-CT non-ionic contrast agent and fluoroquinolones series. The company is headquartered in Taizhou, Zhejiang and currently employs 1,818 full-time employees. The company went IPO on 2016-03-09. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.

Intrinsic Value
15.41 CNY
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Zhejiang Starry Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
336.3m CNY

Based on the financial report for Sep 30, 2025, Zhejiang Starry Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 336.3m CNY.

What is Zhejiang Starry Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
12%

The average annual Cash from Operating Activities growth rates for Zhejiang Starry Pharmaceutical Co Ltd have been 33% over the past three years , 12% over the past five years .

Back to Top